Kite, a Gilead Company, presents long-term CAR T cell therapy data in lymphomas at the 48th EBMT Annual Meeting
Kite, a Gilead Company, presents long-term CAR T cell therapy data in lymphomas at the 48th EBMT Annual Meeting
- Primary analysis of pivotal data on earlier use of CAR T cell therapy as second-line treatment in relapsed/refractory diffuse large B cell lymphoma
- Long-term overall survival and safety management data in relapsed/refractory diffuse large B cell lymphoma after two or more lines of therapy
- Two-year follow-up results in relapsed/refractory indolent non-Hodgkin lymphoma after two or more lines of therapy
“Kite’s presentations at the 48th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting demonstrate the strength of our blood cancer cell therapy development programme,” said Dick Sundh, Vice President, Head of Australia, Canada and Europe (ACE), Kite. “Long-term follow-up in follicular lymphoma and diffuse large B cell lymphoma are complemented by important safety management results and pivotal data in the first head-to-head study of a CAR T cell therapy in second-line relapsed/refractory diffuse large B cell lymphoma.”
ZUMA-1: Axicabtagene Ciloleucel
Five-year overall survival results and data from a safety cohort evaluating prophylactic steroid use in the pivotal ZUMA-1 trial of axicabtagene ciloleucel (Yescarta®) in patients with relapsed/refractory diffuse large B cell lymphoma.
ZUMA-7: Axicabtagene Ciloleucel
The primary analysis of the pivotal Phase 3 ZUMA-7 study evaluating the safety and efficacy of axicabtagene ciloleucel versus current standard of care for second-line therapy in relapsed/refractory diffuse large B cell lymphoma will be presented alongside patient-reported outcomes.
ZUMA-5: Axicabtagene Ciloleucel
An oral session with long-term (two-year) follow-up results from the pivotal ZUMA-5 study of axicabtagene ciloleucel for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma, including follicular lymphoma, after two or more lines of therapy.
Abstracts published at the meeting will include:
|
Study Name and Session Number |
Abstract Title Primary Author |
|
Oral Session |
|
|
ZUMA-5 Two-Year Follow-Up
Oral Session Number: OS08-01
Tue 22 Mar, 16:00-16:09 CET |
Long-Term Follow-Up Analysis Of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) In Patients With Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (INHL)
Sattva Neelapu |
|
ZUMA-1 Cohort 6 One-Year
Oral Session Number: OS08-02 Tue 22 Mar, 16:09-16:18 CET |
Prophylactic Corticosteroid Use With Axicabtagene Ciloleucel (Axi-Cel) In Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 1-Year Follow-Up Of ZUMA-1 Cohort 6 (C6)
Olalekan Oluwole |
|
ZUMA-7 Elderly
Oral Session Number: OS08-05 Tue 22 Mar, 16:36-16:45 CET |
Superiority Of Axicabtagene Ciloleucel (Axi-Cel) In Second-Line (2L) Large B-Cell Lymphoma (LBCL) In The Elderly
Tom van Meerten |
|
ZUMA-7 Primary Analysis
Oral Session Number: OS13-06 Wed 23 Mar, 11:30-11:39 CET |
Primary Analysis Of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-Of-Care (SOC) Therapy In Patients With Relapsed/Refractory Large B-Cell Lymphoma
Fred Locke |
|
E-Poster Presentation |
|
|
ZUMA-7 Patient-Reported Outcomes
Poster Number: P104 |
Patient-Reported Outcomes In ZUMA-7, A Phase 3, Randomized, Open-Label Study Evaluating The Efficacy Of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-Of-Care Therapy In Relapsed/Refractory Large B-Cell Lymphoma
Mahmoud Elsawy |
|
ZUMA-1 Five-Year Overall Survival
Poster Number: P093 |
Long-Term (5 Year) Overall Survival In ZUMA-1, The Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) In Patients With Refractory Large B-Cell Lymphoma (LBCL)
Caron Jacobson |
|
ZUMA-12 Primary Analysis
Poster Number: P089 |
Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy In Patients With High-Risk Large B-Cell Lymphoma (LBCL)
Sattva Neelapu |
|
Health Economics and Outcomes Research: ZUMA-1 Value of Uncertainty
Poster Number: P657 |
How Long Is Long-Enough? An Investigation Into The Relationship Between Trial Maturity And Uncertainty In Cost-Effectiveness, The Case Of Axicabtagene Ciloleucel In 3L DLBCL
S. Vadgama |
|
Health Economics and Outcomes Research: ZUMA-7 US CEM/BIM
Poster Number: P090 |
Cost-Effectiveness of Axicabtagene Ciloleucel As Second-Line Therapy For Patients Large B-Cell Lymphoma (LBCL) In The United States
Patrick Johnston |
For more information visit: https://www.ebmt.org/annual-meeting. This site does not belong to Kite.
Available spokespeople:
o Dick Sundh, Vice President, Head of ACE, Kite
o Dominique Tonelli, Executive Director, Head of Medical Affairs, ACE, Kite
For more information or to arrange an interview contact Cressida Robson on +44 7341 789 204 or cressida.robson@gilead.com.
Editor Details
-
Company:
- PharmiWeb.com
-
Name:
- PW Editor
- Email:
-
Telephone:
- +441344851506
